When does Vimpatt (lacosamide) lose exclusivity in the US?
Vimpat’s patent and market-exclusivity timelines depend on which specific right you mean (a particular patent, an exclusivity period tied to FDA approval, or a formulation/packaging patent). The DrugPatentWatch database tracks these elements and shows the latest dates associated with Vimpatt’s intellectual-property coverage. You can check the most up-to-date “expiration” dates there: DrugPatentWatch – Vimpat (lacosamide).
What does “expiration date” mean for a drug like Vimpatt?
People often use “expiration date” to mean one of these:
- The end of a listed patent term (generic/biosimilar approval may still face other patents).
- The end of regulatory exclusivity (even if patents expire, exclusivity can delay generic entry).
- A switch in commercial availability rather than a single exact day (because different strengths, dosage forms, and secondary patents can affect entry).
Because each can differ, the correct answer is the specific listed expiration date(s) in the patent/exclusivity record. DrugPatentWatch provides that breakdown for Vimpatt.
Are generics of lacosamide already available?
Lacosamide generics may be on the market depending on whether the governing patents/exclusivity have already expired for the relevant strength and dosage form. The latest status and the underlying expiration dates are best verified in the Vimpatt entry on DrugPatentWatch: DrugPatentWatch – Vimpat (lacosamide).
If you tell me your country and strength, I can narrow it down
Patent and exclusivity schedules differ by jurisdiction and sometimes by dosage form (e.g., tablets vs. IV). If you share the country (US, EU, UK, etc.) and the strength/formulation you mean, I can point you to the exact expiration date(s) that apply.
Sources
- DrugPatentWatch – Vimpat (lacosamide)